Join Evolve at the Veterinary Innovation Summit 2017

Evolve BioSystems is proud to participate in the Veterinary Innovation Summit, taking place April 28-30th in College Station, TX.

The Veterinary Innovation Summit, an event co-hosted by Texas A&M University and the North American Veterinary Community (NVAC), is a collision of different ideas, technologies, organizations, and people all committed to advancing the future of the veterinary profession. 

Come visit the Evolve booth to learn how our animal health product, GlycoGuard™, supports a healthy gut microbiome in nursing foals. GlycoGuard, the first oral activated microbial gel for newborn foals, is a combination of two activated beneficial bacteria, B. infantis and L. plantarum, which selectively thrive on mare's milk. When provided to nursing foals immediately after birth, GlycoGuard works along with mare's milk to properly establish the intestinal microflora during these important first few weeks of life.

More details on the conference:

To learn more about GlycoGuard, visit us at:

Evolve BioSystems Contact
Dr. Duane Maye
Director, Animal Health

About Evolve BioSystems
Evolve BioSystems, Inc. is a privately-held microbiome company dedicated to developing the next generation of products to establish, restore, and maintain a healthy human gut microbiome. Evolve is a spin-out from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components. Having led to the discovery and development of products to resolve infant gut dysbiosis, Evolve’s discovery platform is now being applied to solving gut dysbiosis throughout the human life cycle as well as in various animal species. Evolve completed a $9 million Series A capital raise in 2015 and has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering.  In addition, Evolve is undertaking further clinical studies to build out its offering of microbiome-based solutions across a spectrum of unmet clinical needs.

Tracy Shafizadeh